Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.

Owens & Minor, Inc.

(RTTNews) - Healthcare solutions company Owens & Minor, Inc. (OMI) reported Monday a net loss for the second quarter that sharply widened to $869.06 million or $11.30 per share from $31.91 million or $0.42 per share in the prior-year quarter.
Loss from continuing operations for the quarter was $83.82 million or $1.09 per share from $6.74 million or $0.09 per share last year.
Excluding items, income from continuing operations $0.26 per share, compared to $0.25 per share in the year-ago quarter.
Net revenues for the quarter grew to $681.92 million from $660.40 million in the year-ago quarter.
On average, six analysts polled expected the company to report earnings of $0.28 per share on revenues of $2.73 billion for the quarter. Analysts' estimates typically exclude special items.
The Company said it will provide its 2025 financial outlook for continuing operations during itsearnings conference callthis morning at 8:30 a.m. EDT.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Owens & Minor Q2 Net Loss Sharply Widens

ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.66%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.36 per share when it actually produced earnings of $2.37, delivering a surprise of +0.42%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
ResMed, which belongs to the Zacks Medical - Products industry, posted revenues of $1.35 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.87%. This compares to year-ago revenues of $1.22 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
ResMed shares have added about 21.3% since the beginning of the year versus the S&P 500's gain of 8.2%.
What's Next for ResMed?
While ResMed has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for ResMed was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $1.32 billion in revenues for the coming quarter and $10.46 on $5.52 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Owens & Minor (OMI), is yet to report results for the quarter ended June 2025.
This medical supply distributor is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of -25%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Owens & Minor's revenues are expected to be $2.73 billion, up 2.3% from the year-ago quarter.
Should You Invest in ResMed Inc. (RMD)?
Before you invest in ResMed Inc. (RMD), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates

(RTTNews) - Below are the earnings highlights for Owens & Minor (OMI):
Earnings: -$296.12 million in Q4 vs. $17.78 million in the same period last year. EPS: -$3.84 in Q4 vs. $0.23 in the same period last year. Excluding items, Owens & Minor reported adjusted earnings of $43.29 million or $0.55 per share for the period.
Analysts projected $0.52 per share Revenue: $2.696 billion in Q4 vs. $2.656 billion in the same period last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Owens & Minor Q4 Earnings Summary

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DigitalBridge Group Inc (Symbol: DBRG), where a total volume of 14,888 contracts has been traded thus far today, a contract volume which is representative of approximately 1.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 68.1% of DBRG's average daily trading volume over the past month, of 2.2 million shares. Especially high volume was seen for the $10 strike call option expiring March 21, 2025, with 3,168 contracts trading so far today, representing approximately 316,800 underlying shares of DBRG. Below is a chart showing DBRG's trailing twelve month trading history, with the $10 strike highlighted in orange:
Owens & Minor, Inc. (Symbol: OMI) saw options trading volume of 9,762 contracts, representing approximately 976,200 underlying shares or approximately 65.4% of OMI's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $7 strike put option expiring March 21, 2025, with 4,518 contracts trading so far today, representing approximately 451,800 underlying shares of OMI. Below is a chart showing OMI's trailing twelve month trading history, with the $7 strike highlighted in orange:
And First Solar Inc (Symbol: FSLR) saw options trading volume of 15,982 contracts, representing approximately 1.6 million underlying shares or approximately 65% of FSLR's average daily trading volume over the past month, of 2.5 million shares. Especially high volume was seen for the $170 strike call option expiring February 21, 2025, with 1,332 contracts trading so far today, representing approximately 133,200 underlying shares of FSLR. Below is a chart showing FSLR's trailing twelve month trading history, with the $170 strike highlighted in orange:
For the various different available expirations for DBRG options, OMI options, or FSLR options, visit StockOptionsChannel.com.
Also see:
Dividend Aristocrats List
Top Ten Hedge Funds Holding JPC
TEO Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Thursday Option Activity: DBRG, OMI, FSLR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Owens & Minor, Inc. (Symbol: OMI), where a total volume of 9,218 contracts has been traded thus far today, a contract volume which is representative of approximately 921,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 182% of OMI's average daily trading volume over the past month, of 506,490 shares. Especially high volume was seen for the $11 strike put option expiring March 21, 2025, with 3,003 contracts trading so far today, representing approximately 300,300 underlying shares of OMI. Below is a chart showing OMI's trailing twelve month trading history, with the $11 strike highlighted in orange:
General Motors Co (Symbol: GM) options are showing a volume of 140,631 contracts thus far today. That number of contracts represents approximately 14.1 million underlying shares, working out to a sizeable 125.3% of GM's average daily trading volume over the past month, of 11.2 million shares. Especially high volume was seen for the $50 strike call option expiring February 07, 2025, with 9,140 contracts trading so far today, representing approximately 914,000 underlying shares of GM. Below is a chart showing GM's trailing twelve month trading history, with the $50 strike highlighted in orange:
And NVIDIA Corp (Symbol: NVDA) options are showing a volume of 3.7 million contracts thus far today. That number of contracts represents approximately 365.4 million underlying shares, working out to a sizeable 122.9% of NVDA's average daily trading volume over the past month, of 297.4 million shares. Particularly high volume was seen for the $120 strike call option expiring February 07, 2025, with 128,275 contracts trading so far today, representing approximately 12.8 million underlying shares of NVDA. Below is a chart showing NVDA's trailing twelve month trading history, with the $120 strike highlighted in orange:
For the various different available expirations for OMI options, GM options, or NVDA options, visit StockOptionsChannel.com.
Also see:
KRON Average Annual Return
MWK market cap history
News Corp market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Monday Option Activity: OMI, GM, NVDA

(RTTNews) - Owens & Minor (OMI) will host a conference call at 8:30 AM ET on November 4, 2024, to discuss Q3 24 earnings results.
To access the live webcast, log on to https://investors.owens-minor.com/events-and-presentations/
To listen to the call, dial 1-888-300-2035 (US) or 1-646-517-7437 (International), Access code 1058917.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Owens & Minor Q3 24 Earnings Conference Call At 8:30 AM ET

(RTTNews) - While reporting financial results for the third quarter on Monday, healthcare solutions company Owens & Minor, Inc. (OMI) narrowed its adjusted earnings and revenue guidance range for the full-year 2024.
For fiscal 2024, Owens & Minor now projects adjusted earnings in a range of $1.45 to $1.55 per share on revenues between $10.6 billion and $10.8 billion.
Previously, the company expected adjusted earnings in the range of $1.40 to $1.70 per share on revenues between $10.5 billion and $10.9 billion.
On average, seven analysts polled by Thomson Reuters expect the company to report earnings of $1.59 per share on revenues of $10.71 billion for the quarter. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Owens & Minor Narrows FY24 Outlook Range - Update

(RTTNews) - Below are the earnings highlights for Owens & Minor (OMI):
Earnings: -$12.77 million in Q3 vs. -$6.43 million in the same period last year. EPS: -$0.17 in Q3 vs. -$0.08 in the same period last year. Excluding items, Owens & Minor reported adjusted earnings of $33.2 million or $0.42 per share for the period.
Analysts projected $0.41 per share Revenue: $2.721 billion in Q3 vs. $2.592 billion in the same period last year.
-Guidance: Full year EPS guidance: $1.45 - $1.55 Full year revenue guidance: $10.6 Bln-$10.8 Bln
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Owens & Minor Q3 Earnings Summary

(RTTNews) - Owens & Minor (OMI) announced that Jonathan Leon has been named Executive Vice President, Chief Financial Officer, effective immediately. He will maintain corporate treasurer responsibilities while a search for successor is underway. Leon has been with the company since 2017, most recently serving as Interim Chief Financial Officer and Corporate Treasurer since June 2024.
"After a comprehensive process, the Board and I unanimously agreed that Jon is the ideal candidate to serve as Owens & Minor's next Chief Financial Officer," said Edward Pesicka, President and CEO of Owens & Minor.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Owens & Minor Names Jonathan Leon CFO - Quick Facts

Cardinal Health, Inc. CAH is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.
In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%.
Q4 Estimates
For the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter’s reported figure. The same for revenues is pinned at $58.72 billion, implying growth of 9.9% year over year.
Factors to Note
From the fiscal third quarter of 2024, Cardinal Health started reporting its results under new operating segments — Pharmaceutical and Specialty solutions, Global Medical Products and Distribution (GMPD) segment, nuclear at-Home and OptiFreight.
The third quarter of fiscal 2024 witnessed an uptick in revenues in the Pharmaceutical segment, which amounted to approximately $50.7 billion, up 9% on a year-over-year basis. The Pharmaceutical Distribution and Specialty Solutions segment’s performance highlighted branded pharmaceutical sales growth from existing customers. The segment's profit increased 4% during the fiscal third quarter. This momentum is likely to have continued in the fiscal fourth quarter as well. Moreover, the rising demand for GLP-1 medications is likely to have acted as a tailwind.
Higher contributions from brand and specialty products, as well as the effectiveness of the generics program, drove the positive outcome of the pharmaceutical segment in the last reported quarter. This trend is likely to have continued in the to-be-reported quarter as well.
Medical segment’s revenues grew 4% year over year in the last reported quarter, driven by growth in at-Home Solutions and GMPD. The segment’s profit was $20 million in the fiscal third quarter. This upside was driven by an improvement in net inflationary impacts, including mitigation initiatives, which are likely to have boosted the medical segment’s results in the fiscal fourth quarter as well.
In March 2024, Cardinal Health completed the acquisition of Specialty Networks, which is likely to expand the company’s offerings with physicians in the areas of urology, GI, and rheumatology. Specialty Networks is providing a proven platform in PPS analytics that the company is likely to further invest in fiscal 2025 and look to extend to other therapeutic areas such as oncology.
Per the third-quarterearnings call CAH’s integration of Specialty Networks is underway, and the reaction from the providers the company serves has been extremely encouraging. The platform's insight generation capabilities for clinicians are robust, which is likely to accelerate CAH’s upstream data and research opportunities with biopharma manufacturers. The company is expected to provide further updates in this regard in the to-be-reported quarter.
The company announced its new distribution center being built in South Carolina, which, per management, features the fastest order fulfillment system per square foot in the market. The center is scheduled to open by early next fiscal year. New distribution centers are likely to aid the company’s supply chain, thus improving revenues. Cardinal Health is likely to provide further updates in this regard in the to-be-reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Cardinal Health this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.17%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: Cardinal Health currently carries a Zacks Rank #3.
Cardinal Health, Inc. Price and EPS Surprise
Cardinal Health, Inc. price-eps-surprise | Cardinal Health, Inc. Quote
Stocks to Consider
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
Phibro Animal Health PAHC has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The stock has risen 59.5% year to date. PAHC’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 2.30%.
Owens & Minor OMI has an Earnings ESP of +1.54% and a Zacks Rank of 2 at present.
The stock has lost 14.6% year to date. OMI’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 11.99%.
ResMed RMD has an Earnings ESP of +2.85% and a Zacks Rank of 3 at present.
The stock has risen 16% year to date. RMD’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 2.81%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Owens & Minor, Inc. (OMI) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.